Tactile Medical (TCMD) Q1 2026 earnings review
Lymphedema Turnaround Drives Q1 Beat and Guidance Raise
Tactile Medical delivered a robust 26Q1, with total revenue accelerating to 23% YoY growth ($75.3M). The core Lymphedema segment completed a remarkable turnaround—from a 3% decline a year ago to 23% growth today—proving that last year's painful sales force restructuring and CRM implementation were effective investments. Operating leverage materialized cleanly, driving gross margins up 250 basis points and swinging Adjusted EBITDA to a positive $3.7M. While management raised full-year revenue guidance, the implied math suggests meaningful growth deceleration in the back half of the year as the company faces tougher comparables and new Medicare prior authorization hurdles.
🐂 Bull Case
The Lymphedema division successfully re-accelerated to 23% YoY growth, definitively proving that last year's investments in a new CRM and expanded sales headcount are yielding high productivity.
The company secured FDA 510(k) clearance for its next-generation AffloVest, setting the stage for a product cycle upgrade in the 2026-2027 respiratory season.
🐻 Bear Case
Despite a Q1 revenue beat of 23%, the full-year guidance raise of $3M implies revenue growth will decelerate to the 7-8% range for the remaining three quarters of 2026.
A new Medicare prior authorization requirement creates near-term execution risk, while Q1 profitability was weighed down by $1.0M in unexpected litigation costs.
⚖️ Verdict: 🟢
Bullish. The company executed flawlessly on its turnaround plan, successfully reversing the Lymphedema segment's contraction while structurally improving gross margins.
Key Themes
Lymphedema Recovery is Complete
Lymphedema sales accelerated sequentially for the fifth consecutive quarter, hitting 23% YoY growth ($62.2M). This compares to a 3% decline in 25Q1. The CRM disruption and sales force vacancy issues that crippled last year's Q1 have been resolved, yielding a highly productive, fully resourced go-to-market engine.
Airway Clearance Normalizes as Next-Gen Clears FDA
Airway clearance sales normalized to 22% YoY growth ($13.0M), decelerating from the explosive 50-70% growth rates seen in mid-2025. This normalization was expected by management. Crucially, the company secured FDA 510(k) clearance for the next-generation AffloVest, providing a fresh catalyst to maintain market share against DMEs.
Operating Leverage Materializes
Gross margins expanded 250 bps to 76.5%, and operating expenses grew 19% compared to the 23% revenue increase. This disciplined execution allowed Adjusted EBITDA to reverse from a $0.3M loss in 25Q1 to a positive $3.7M this quarter, proving the scalability of the company's recent strategic investments.
Implied Deceleration & Prior Auth Risk
While Q1 was strong, the revised FY26 revenue guidance implies ~7-8% YoY growth for the remainder of the year. This sharp deceleration reflects both tougher YoY comparables (H2 2025 grew 17-21%) and friction from a new Medicare prior authorization requirement for pneumatic compression devices. Management specifically noted they deployed new AI-enabled operational capabilities to handle this requirement, but execution risk remains high as the industry adapts.
Litigation and Integration Costs Weigh on GAAP Results
The Q1 Adjusted EBITDA reconciliation backed out $1.0M in unforecasted litigation-related costs and $0.8M in acquisition and integration costs. While adjusted metrics look strong, these cash expenses contributed to an ongoing GAAP Net Loss of $1.8M. The nature of the litigation was not disclosed in the press release and warrants monitoring.
Other KPIs
Accelerating. Up from 74.0% in 25Q1 and 75.9% for the full year 2025. This 250 bps expansion highlights improved pricing, manufacturing leverage, or favorable product mix shifting toward higher-margin advanced pumps.
Down from $83.4M at the end of FY25. The cash burn was primarily driven by $6.2M in net acquisition payments for LymphaTech and $1.1M in share repurchases. The company remains debt-free.
Guidance
Accelerating vs prior expectations. The guidance was raised from a prior range of $357M-$365M. The new midpoint represents 10.5% YoY growth over FY25's $329.5M. Because Q1 grew 23%, the implied growth for Q2-Q4 is decidedly lower (~7.6%), reflecting tougher base effects.
Stable. Management maintained its prior guidance range. The $50M midpoint implies an 11.6% YoY growth from FY25's $44.8M. The lack of an EBITDA raise despite the revenue raise suggests management is absorbing integration costs or planning additional commercial investments in H2.
Key Questions
Medicare Prior Authorization Impact
You highlighted the rollout of your AI-enabled platform to handle the new Medicare prior authorization requirement for PCDs. Can you quantify any impact this had on order processing times or patient leakage in the weeks since the rule took effect?
Litigation Expenses
The Adjusted EBITDA reconciliation includes $1.0 million in litigation-related costs. What is the nature of this litigation, and should we expect it to be a recurring expense through 2026?
Next-Gen AffloVest Commercialization
With the 510(k) clearance secured for the next-generation AffloVest, what is the timeline for the commercial launch, and how will it impact gross margins in the Airway segment?
H2 Growth Baseline
Lymphedema grew an impressive 23% this quarter against an easy comp. As we move into the back half of the year against much tougher 15-20% comparisons, what do you view as the structural, normalized growth rate for this segment?